Navigation Links
Inverseon Focuses on Mucous and Smoking Cessation
Date:1/12/2012

SAN FRANCISCO, Jan. 12, 2012 /PRNewswire/ -- Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, it is focused on smoking cessation as the initial indication for INV102.

William J. Garner, MD, Chairman, said, "The prioritization of smoking cessation, and also an inhaled COPD program, makes sense for Inverseon given the regulatory hurdles in key markets. We credit Dr. Glass for this refinement of our priorities. Mitchell Glass's extensive drug development background, relationships with the respiratory community, and experience with the strategic development and commercialization of therapeutics will be a major asset for Inverseon as the company advances its lead product (INV102) towards commercialization."

"Inverseon has provided critical support for the use of beta-adrenergic receptor inverse agonists for treating respiratory diseases. The founder's basic scientific breakthroughs provide a rational explanation for our previous success in developing carvedilol for heart failure while I was at SmithKline Beecham and provide a rationale for using INV102 for treating COPD. Two Phase II asthma trials are supportive of further development for chronic pulmonary diseases," said Dr. Glass. "We are now collaborating with granting agencies for further development of INV102 in asthma and preparing for expanded internal Phase II clinical trials demonstrating safety and efficacy of INV102 as a treatment to aid smoking cessation and chronic bronchitis."

About Inverseon, Inc.
Founded in 2004, Inverseon is a privately held company with product development programs in Phase II that target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as COPD and asthma. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD
bill@inverseon.com  
http://www.inverseon.com  
(917) 653-0470

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
2. Nature article focuses on tinnitus treatment
3. ONR lecture focuses on Brazils growth in global science and technology
4. Florida Water Resources Annual Conference Focuses on Numeric Nutrient and Other Water Issues
5. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
6. Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
11. ECBCs Environmental BioMonitoring Laboratory Focuses on the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... ... 24, 2017 , ... It is well established that ligand ... broad application of this cellular target engagement concept to drug discovery has been ... stabilization assays are valuable methods for particular applications, but they can require target-specific ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):